Field Medical Advances with $35 Million Series B to Transform VT Treatment
Deal News | Jul 01, 2025 | PR Newswire Cision Field Medical, Inc.
Field Medical, Inc., a clinical-stage company specializing in next-generation pulsed field ablation (PFA) technology, announced the successful close of a $35 million Series B financing round. The funding was co-led by BioStar Capital and Cue Growth, with additional participation from existing investors. This capital will support the initiation of the pivotal VERITAS trial, enhance the development of the FieldForce Ablation System, and augment clinical and regulatory capabilities. Founded in 2022 by Dr. Steven Mickelsen, Field Medical is at the forefront of addressing complex cardiac arrhythmias using its proprietary FieldBending energy. The recent financing aligns with the company's growth trajectory, evidenced by updates to its Board of Directors, featuring industry veterans and medical technology experts. Maintaining a strong momentum following promising pilot data and strategic partnerships, Field Medical aims to redefine ventricular tachycardia (VT) treatment, a field with significant unmet clinical demand.
Sectors
- Healthcare Technology
- Venture Capital
Geography
- United States – Field Medical, as well as the headquarters mentioned as Cardiff-by-the-Sea, California, are based in the United States, making this the primary geographic focus.
Industry
- Healthcare Technology – Field Medical is involved in developing advanced medical technologies for cardiac arrhythmia treatment, placing it within the Healthcare Technology sector.
- Venture Capital – The involvement of BioStar Capital and Cue Growth in the Series B funding round associates the article with the Venture Capital sector.
Financials
- $35 million – The amount raised in Field Medical's Series B financing round.
- $75 million – The total amount raised by Field Medical to date.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Field Medical, Inc. | Target company | Company | A clinical-stage company advancing pulsed field ablation technology for complex cardiac arrhythmias. |
| BioStar Capital | Co-lead investor | Company | A venture capital firm that co-led the Series B financing round for Field Medical. |
| Cue Growth | Co-lead investor | Company | Another venture capital firm that co-led the Series B financing round for Field Medical. |
| Steven Mickelsen, MD | Founder and CEO of Field Medical | Person | Founder and leader of Field Medical with expertise in pulsed field ablation technologies. |
| Louis Cannon, MD | Founder and senior managing director of BioStar Capital | Person | A key figure supporting Field Medical through BioStar Capital's investment. |
| Oskar Dadason | CFO of Field Medical | Person | Financial leader at Field Medical, commenting on the company's momentum and business fundamentals. |